Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humana Inc. (HUM)

Law Offices of Howard G. Smith reminds investors of the upcoming August 2, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”).

Investors suffering losses on their Humana investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to

On June 13, 2023, one of Humana’s primary competitors, UnitedHealth Group Inc. (“UnitedHealth”) revealed that it was seeing “higher levels” of outpatient care activity due, potentially, to “pent-up demand or delayed demand being satisfied.” On this news, Humana’s stock price fell $57.63, or 11.2%, to close at $455.00 per share on June 14, 2023, thereby injuring investors.

Then, on June 16, 2023, Humana confirmed that it was also experiencing “higher than anticipated non-inpatient utilization trends, predominately in the categories of emergency room, outpatient surgeries, and dental services, as well as inpatient trends that have been stronger than anticipated in recent weeks, diverging from historical seasonality patterns.” The Company further warned that it now expected reduced profitability and “assume[d] it will continue to experience moderately higher-than-expected trends for the remainder of the year.” On this news, Humana’s stock price fell $18.20, or 3.9%, to close at $445.65 per share on June 16, 2023.

Then, on January 18, 2024, Humana released its fourth quarter and full year 2023 preliminary financial results, revealing that its benefits expense ratio had increased to approximately 91.4% for the fourth quarter of 2023 and approximately 88% for the full year 2023. As a result, the Company’s 2023 adjusted EPS were more than $2 per share less than what the Company had previously predicted. On this news, Humana’s stock price fell $35.78, or 8%, to close at $411.98 per share on January 18, 2024.

Then, on January 25, 2024, Humana disclosed that it expected higher levels of medical costs for all of 2024, and, as a result, the Company expected 2024 adjusted EPS of $16 per share -- $10 less than the previous year and $13 below analysts’ expectations. On this news, Humana’s stock price fell $47.04, or 11.7%, to close at $355.36 per share on January 25, 2024, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) downplayed pressures on the Company’s adjusted EPS resulting from increased medical costs associated with pent-up demand for healthcare procedures (especially as COVID concerns abated) which, contrary to the Company’s assurances, resulted in increased utilization rates and costs; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Humana common stock during the Class Period, you may move the Court no later than August 2, 2024 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to, or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.